Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2016 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
|Live BSE Quotes||Oct 27, 2016 (Close)|
|Price (Rs)745.20||Open (Rs) 744.90||High (Rs) 751.00||Low (Rs) 737.55|
|% Change0.76||Volume 150,239||Value (Rs) 112,079,167||52-Week H/L 907.55 / 706.40|
|Live NSE Quotes||Oct 27, 2016 (Close)|
|Price (Rs)746.90||Open (Rs) 742.00||High (Rs) 750.70||Low (Rs) 737.20|
|% Change1.11||Volume 2,686,399||Value (Rs) 2,004,897,193||52-Week H/L 907.50 / 704.00|
|EPS (Rs)* 26.05||P/E Ratio (x) 28.60||Market Cap (Rs m) 1,793,512.34||P/BV (x) 5.71|
|*Trailing 12 months earnings, excluding extraordinary / exceptional items.||BSE Sensex | CNX Nifty|
|SUN PHARMA Stock Price Chart (Rs) - 1 Year|
Quote & Graph
S&P BSE SENSEX
Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.
Sun Pharma has announced its 3QFY16 results. Net sales have grown by 2.3% YoY, while net profits surged by 258% YoY. Here is our analysis of the results.
Sun Pharma has announced its 2QFY16 results. The company has reported a 14.7% YoY decline in the topline, while net profits plummeted by 46% YoY. Here is our analysis of the results.
Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.
Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.More Views on News
A brief discussion on one BHK apartments going for Rs 1.8 crore in Mumbai and why it makes no sense.
Why we are bullish on some small cap stocks despite the high index PE.
Using Directional Movement Indicators to build your trading system
PersonalFN explains why top performing mutual fund schemes may not always be the perfect fit for your investment portfolio.
Why the PE ratios of mid caps and small caps are currently at such lofty levels.More